Language

2018-02-08

BioNTech announces results from tow more studies demonstrating the benefit of breast cancer subtyping using MammaTyper®

• MammaTyper® is superior to local immunohistochemistry (IHC) for measuring local gene expression in order to predict Oncotype DX®-type results1 • Use of MammaTyper® subtyping for prognosis of breast cancer suggests that endocrine therapy¬ may be adequate for patients with a low risk of relapse2 • This study demonstrated that MammaTyper® is a cost-effective method …


2017-08-10

BioNTech Diagnostics GmbH and Metropolis Healthcare Ltd. Announce Partnership to commercialize new Breast Cancer Stratification Test

Strategic partnership to make BioNTech´s mRNA-based molecular breast cancer stratification test, MammaTyper®, commercially available in India, Sri Lanka, Kenya, Mauritius, Ghana and Zambia through Metropolis’ medical testing service laboratorie Partners combine their expertise in in vitro diagnostics and clinical testing services to enable precise characterization of breast cancer tumor types Mainz, Germany and Mumbai, India, …


2017-05-15

BioNTech announces positive results of an international reproducibility study with MammaTyper®

International multicenter study in ten pathology laboratories in the U.S., Canada, Europe and Asia MammaTyper® provides highly reproducible quantitative results of the mRNA expression status of the four biomarkers HER2 (ERBB2), ER (ESR1), PR (PGR) and Ki-67 (MKI67) Mainz, May 15, 2017: BioNTech Diagnostics GmbH today announced the publication of an international prospective multicenter study …


2017-02-15

MammaTyper® enables more precise prediction of the response to neoadjuvent chemotherapy compared to manual or digitalized IHC

First comparison of a biomarker analysis by RT-qPCR (MammaTyper®) versus visual or computer-assisted immunohistochemistry (IHC) in subtyping mammary carcinomas Significantly more precise prediction of pathologically complete remission in a neoadjuvant setting with MammaTyper® compared to manual or computer-assisted IHC; better therapy stratification and possible avoidance of unnecessary therapies MammaTyper® provides reliable quantitative determination of MKI67-mRNA …